Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 782 | 0.82 |
| pathways Reactome | 1 pathway; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 9784
Sealed predictions
- SMAD5 in dopamine neurons, braak+0.04 (p 0.927) → +0.46 (p 0.214)receipt 9792
Swarm cases
receipt 9792: SMAD5 in dopamine neurons, braak
- power
- full sample +0.37 (p 0.130, n 18), 95% CI -0.12 to +0.71. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.36 (p 0.142, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.37 (p 0.130, n 18). could be the mix.
- skeptic
- leave-one-out range +0.31 to +0.57, sign flips 0; without severely affected donors +0.37 (p 0.130, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SMAD5 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts